| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 贵州三力制药股份有限公司成立于1995年，是一家集研发、生产和销售于一体的现代化中成药制药企业。公司产品线主要围绕儿科、呼吸系统科、心脑血管科、消化内科等领域，主要产品为开喉剑喷雾剂（儿童型）、开喉剑喷雾剂和强力天麻杜仲胶囊等。其中，核心产品开喉剑喷雾剂（儿童型）、开喉剑喷雾剂均为国家专利产品，在咽喉疾病中成药喷雾剂市场占据较高的市场份额，已在咽喉疾病、儿童用中成药领域形成了一定的品牌知名度。根据南方所的统计，开喉剑喷雾剂（含儿童型）在咽喉疾病中成药喷雾剂市场中连续3年排名第1，在咽喉疾病中成药喷雾剂医院终端市场已连续6年市场排名第1。 贵州三力自成立以来，始终坚持质量第一、恪守信誉、竭诚服务的质量方针，以新版GMP为最低管控标准，精益求精，持续改进。经过长期的发展积累，公司荣获国家高新技术企业、贵州民营企业100强等多项荣誉，多项产品被评为贵州省名牌产品，商标被评为贵州省著名商标，并入选了贵州省知识产权优势培育企业库。 | ||||||||||||||||||||||||
| Main Business | 药品的研发、生产及销售。 | ||||||||||||||||||||||||
| Legal Representative | 张海 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 张千帆 | ||||||||||||||||||||||||
| Solicitors | 北京国枫律师事务所 | ||||||||||||||||||||||||
| Auditors | 大华会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0851-38113395 | ||||||||||||||||||||||||
| Fax No | 0851-38113572 | ||||||||||||||||||||||||
| Website | www.gz-sanli.com | ||||||||||||||||||||||||
| zhangqf@gz-sanli.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 28/04/2020 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.710 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.200 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 3.587 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 5.801B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |